JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.73 2.47

Buy Sell

Overview

Share price change

24h

Current

Min

3.61

Max

3.7800000000000002

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+289.12% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	-4.4M 224M
Previous open	1.26
Previous close	3.73

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2026, 23:08 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 23:07 UTC

Earnings

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:20 UTC

Earnings

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 kwi 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 kwi 2026, 23:22 UTC

Earnings

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 kwi 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 kwi 2026, 22:52 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 kwi 2026, 22:33 UTC

Earnings

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 kwi 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 kwi 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 kwi 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 kwi 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 kwi 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 kwi 2026, 22:05 UTC

Earnings

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 kwi 2026, 21:57 UTC

Earnings

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 kwi 2026, 21:56 UTC

Earnings

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 kwi 2026, 21:55 UTC

Earnings

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 kwi 2026, 21:54 UTC

Earnings

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 kwi 2026, 21:53 UTC

Earnings

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 kwi 2026, 21:49 UTC

Earnings

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

289.12% upside

12 Months Forecast

Average 14.67 USD 289.12%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.